Clinical trials on Atrial Fibrillation

Atrial Fibrillation: An Overview

Atrial Fibrillation (AFib) is a common yet complex type of arrhythmia, or irregular heartbeat, that can lead to blood clots, stroke, heart failure, and other heart-related complications. At its core, AFib involves the two upper chambers of the heart (the atria) beating irregularly and out of coordination with the two lower chambers (the ventricles). This condition affects millions of people worldwide, with numbers increasing as the population ages.

The symptoms of AFib can vary significantly among individuals. Some may experience no symptoms at all, while others may encounter palpitations (sensations of a racing, uncomfortable, irregular heartbeat), weakness, fatigue, reduced ability to exercise, lightheadedness, dizziness, confusion, shortness of breath, and chest pain. However, even in the absence of noticeable symptoms, AFib can still increase the risk of stroke and heart failure, making early detection and management crucial.

Management and treatment of AFib may include medications to control the heart rate and rhythm, blood thinners to prevent blood clots, and procedures like cardioversion or ablation to restore a normal heart rhythm. Lifestyle changes, such as engaging in regular physical activity, maintaining a healthy weight, limiting alcohol intake, and quitting smoking, are also recommended to mitigate symptoms and reduce the risk of complications. Given the complexity and variability of AFib, treatment plans are highly individualized, emphasizing the importance of a collaborative approach between patients and healthcare providers.

Prognosis for Atrial Fibrillation

Atrial Fibrillation (AFib) is a heart condition characterized by an irregular and often rapid heartbeat. The long-term prospects for individuals with AFib vary widely depending on health factors and the presence of underlying heart disease. Generally, AFib is a chronic condition that can increase the risk of stroke, heart failure, and other heart-related complications. While the condition itself isn’t typically life-threatening, its management is crucial to reduce the risk of these serious outcomes. The progression of AFib can be unpredictable; it may manifest as intermittent episodes in some, while others may develop persistent AFib that requires ongoing medical attention. The quality of life can be maintained with proper medical care, and many individuals continue to lead active lives. Nonetheless, the condition necessitates regular monitoring and, in some cases, lifestyle adjustments to accommodate disease management. The prognosis is most favorable when AFib is detected early and managed effectively in collaboration with healthcare professionals.

Complications in Atrial Fibrillation

Atrial Fibrillation (AFib) may lead to several serious health issues. A major concern is the increased risk of stroke. When the heart’s upper chambers quiver unpredictably, blood may pool and form clots. Should a clot break free, it has the potential to travel to the brain, resulting in a stroke. Heart-related complications, such as heart failure, where the heart is unable to pump blood effectively, are also possible. This may manifest as fatigue, shortness of breath, and fluid buildup in the legs and lungs. Furthermore, AFib can be associated with chronic fatigue and palpitations, which can significantly diminish quality of life. Persistent irregular heartbeats may impose additional stress on the heart, potentially exacerbating the condition. Awareness of these complications is crucial, as they can profoundly affect overall health and daily living.

Treatment Methods for Atrial Fibrillation

In the management of Atrial Fibrillation, several non-clinical trial alternatives are recommended. Dietary adjustments, such as the reduction of caffeine and alcohol intake, can help in regulating heart rhythm. The incorporation of heart-healthy foods like fruits, vegetables, and whole grains is also beneficial. Regular physical activity, particularly aerobic exercises, supports overall cardiovascular health.

Pharmacotherapy options include medications to control heart rate and rhythm. Blood thinners may be prescribed to prevent blood clots. It is important to adhere to the prescribed medication regimen and consult with healthcare providers for personalized advice.

Modern technology offers tools like smartphone apps and wearable devices that monitor heart rate and rhythm, assisting individuals in staying informed about their condition. These devices can alert to irregularities, prompting the seeking of medical attention when necessary.

The adoption of these lifestyle changes, adherence to pharmacotherapy, and utilization of modern technology can contribute to the effective management of Atrial Fibrillation. It is always recommended to consult healthcare professionals before making any significant changes to treatment plans.

  • CT-EU-00038623

    Study on single drug therapy in heart patients after stent implantation

    This study is for patients with a heart condition called atrial fibrillation who will be getting a type of heart stent, or tiny tube put into a blood vessel, called a Supraflex Stent. After stenting, patients usually have to take many medications to prevent blood clots. However, these medications can also make people bleed more easily, which is not good. The usual strategy is to give patients three of these medications for a week up to a month, then two for up to 6–12 months, and then just one for the long term. In this study, the investigators will try out a different strategy where only one medication is used at a time. For the first month after stenting, an antiplatelet, a medication to stop blood clotting will be given, then after, an anticoagulant, another type of medication to prevent blood clots will be used. The aim is to see if this approach leads to fewer bleeding problems, while still protecting against blood clots.

    • P2Y12 inhibitor
    • Aspirin
    • DOAC-Direct oral anticoagulant
  • Comparison of milvexian and apixaban in reducing stroke risk in patients with atrial fibrillation

    This study is designed to compare two drugs, Milvexian and Apixaban to reduce the potential risk of stroke for patients suffering from atrial fibrillation, a common heart rhythm disorder. 15500 participants, aged 18 years and older will be invited to partake in this research. Participants will be randomly designated to receive either Milvexian or Apixaban. The study team aims to determine if Milvexian is at least as effective as Apixaban in reducing the risk of combined stroke and Non-central nervous system (CNS) systemic embolism. Furthermore, the research team will evaluate the occurrence rates of various health incidents including major bleeding, various cardiovascular complications, death, and other severe conditions over a 4-year period. The goal is to find out which medication proves safer and more effective in preventing severe health risks linked with this disorder. Study commencement is April 11, 2023, with completion targeted at May 5, 2027.

    • Apixaban
    • Milvexian